Aeglea BioTherapeutics (AGLE) Appoints Marcio Souza to Board of Directors

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Marcio Souza to its board of directors. Mr. Souza serves as the president & chief executive officer of Praxis Precision Medicines, Inc. (NASDAQ: PRAX).

"On behalf of the Aeglea family, I'm pleased to warmly welcome Marcio to our board of directors. We are at a pivotal stage of the company's growth and it is important to have a breadth of experience and diversity of perspectives as we navigate the transition to becoming a commercial-stage company," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Marcio brings extensive global operating and commercial experience, with notable expertise in regions outside of the United States and a proven track record in the rare disease space. The insights and perspectives that Marcio brings to the team will be invaluable in shaping the global commercialization strategy for our portfolio of rare metabolic disease treatments."

"I'm excited to be joining the board of Aeglea, a company committed to having a transformative impact on the lives of patients with rare metabolic diseases," said Mr. Souza. "With Phase 3 data from the Arginase 1 Deficiency program coming in the fourth quarter of 2021 and a second program for Homocystinuria entering the clinic, Aeglea is a company with considerable potential and I look forward to working with the team to bring it to fruition."

Prior to joining Praxis Precision Medicines, Mr. Souza served as chief operating officer at PTC Therapeutics, Inc. from May 2017 to April 2020 and its senior vice president and head of product strategy from July 2016 to May 2017. Previously, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. He also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.

You May Also Be Interested In

• Genco rejects Diana Shipping takeover bid as undervalued
• Genco rejects Diana Shipping bid, calls offer below NAV
• CAE shareholders elect 13 directors, adding Bruce Ross to board